VaxyGen and Georgia State University enter collaboration and licensing agreement

October 27, 2011 at 10:07 am Leave a comment

VaxyGen Manufacturing Services, a Georgia Research Alliance VentureLab company, has entered an exclusive license and collaboration agreement with the Georgia State University Research Foundation to provide the company with exclusive rights to a novel patent for producing and purifying proteins in development as biopharmaceutical and vaccine products.  The collaboration agreement is to commercialize the work of the GSU Biological Process Development and Research Laboratory.  In addition to introducing VaxyGen’s president and CEO David Dodd to researchers at GSU, GRA has invested in equipping the Biological Process laboratory.  Read more here>

Entry filed under: News. Tags: .

GRA Eminent Scholar Rafi Ahmed featured in Khabar Magazine IBM and Georgia Tech launch “One Million Healthy Children” initiative

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Categories

Feeds


Follow

Get every new post delivered to your Inbox.